MDT

100.26

+3%↑

147.57

+3.37%↑

VEEV

238.01

+7.61%↑

HQY

94.97

+1.71%↑

PHR.US

17.21

+0.53%↑

MDT

100.26

+3%↑

147.57

+3.37%↑

VEEV

238.01

+7.61%↑

HQY

94.97

+1.71%↑

PHR.US

17.21

+0.53%↑

MDT

100.26

+3%↑

147.57

+3.37%↑

VEEV

238.01

+7.61%↑

HQY

94.97

+1.71%↑

PHR.US

17.21

+0.53%↑

MDT

100.26

+3%↑

147.57

+3.37%↑

VEEV

238.01

+7.61%↑

HQY

94.97

+1.71%↑

PHR.US

17.21

+0.53%↑

MDT

100.26

+3%↑

147.57

+3.37%↑

VEEV

238.01

+7.61%↑

HQY

94.97

+1.71%↑

PHR.US

17.21

+0.53%↑

Home・Akciju saraksts・Revvity Inc

Revvity Inc

Slēgts

SektorsVeselības aprūpe

104.95 2.85

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

100.9

Max

106.09

Galvenie mērījumi
By Trading Economics
Ienākumi	-8.6M 47M
Pārdošana	-21M 699M
P/E Sektora vidējais	50.057 88.032
EPS	0.4
Dividenžu ienesīgums	0.29
Peļņas marža	6.675
Darbinieki	11,000
EBITDA	-14M 181M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+6.51% upside

Dividendes
By Dow Jones
Dividenžu ienesīgums Sektora vidējais	0.29% 2.26%
Nākamie ieņēmumi	2026. g. 30. janv.
Nākamais dividenžu datums	2026. g. 6. febr.
Nākamais Ex dividenžu datums	2026. g. 16. janv.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-5.8M 11B
Iepriekšējā atvēršanas cena	102.1
Iepriekšējā slēgšanas cena	104.95

Ziņu noskaņojums

By Acuity

24%

76%

51 / 373 Rangs Healthcare

Revvity Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 6. janv. 21:14 UTC

Galvenie tirgus virzītāji

Ventyx Biosciences Gains on Report of Possible $1 Billion Eli Lilly Deal

2026. g. 6. janv. 19:23 UTC

Iegādes, apvienošanās, pārņemšana

OneStream to Go Private Through $6.4 Billion Hg Acquisition

2026. g. 6. janv. 17:41 UTC

Galvenie tirgus virzītāji

Blink Charging Shares Rise as EV Chargers Begin Accepting Cryptocurrency

2026. g. 6. janv. 15:46 UTC

Iegādes, apvienošanās, pārņemšana

Advent International Leads InPost Takeover Offer, Sky News Says

2026. g. 6. janv. 15:37 UTC

Galvenie tirgus virzītāji

Terrestrial Energy Shares Rise After DOE Agreement For Nuclear Plant Development

2026. g. 6. janv. 23:46 UTC

Tirgus saruna

Nikkei May Decline After Hitting Record High -- Market Talk

2026. g. 6. janv. 23:35 UTC

Tirgus saruna

Gold Edges Higher Amid Ongoing Geopolitical Tensions -- Market Talk

2026. g. 6. janv. 23:19 UTC

Tirgus saruna

Greatland 2Q Gold Output Strong, Sales Soft -- Market Talk

2026. g. 6. janv. 22:53 UTC

Tirgus saruna

WiseTech, REA and CAR Look Best Insulated From AI Threat -- Market Talk

2026. g. 6. janv. 22:03 UTC

Iegādes, apvienošanās, pārņemšana

Staar Surgical: Merger Proposal Received 14.9M Votes For and 27.3M Against

2026. g. 6. janv. 22:03 UTC

Iegādes, apvienošanās, pārņemšana

Staar Surgical, Which Earlier Reported Stockholder Rejection of Sale to Alcon, Reports Vote Totals

2026. g. 6. janv. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 6. janv. 21:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 6. janv. 21:12 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2026. g. 6. janv. 21:12 UTC

Tirgus saruna

Commodity Demand Helps Canada Reduce Reliance on Trade With U.S. -- Market Talk

2026. g. 6. janv. 20:59 UTC

Galvenie tirgus virzītāji

Iegādes, apvienošanās, pārņemšana

Ventyx Biosciences Gains on Report of Possible $1B Eli Lilly Deal

2026. g. 6. janv. 20:40 UTC

Iegādes, apvienošanās, pārņemšana

Acquisition of Ventyx Would Bring Lilly Into Emerging Category of Pills for Inflammation-Related Conditions -- WSJ

2026. g. 6. janv. 20:40 UTC

Iegādes, apvienošanās, pārņemšana

Eli Lilly Nears Deal for Biotech Ventyx -- WSJ

2026. g. 6. janv. 20:40 UTC

Iegādes, apvienošanās, pārņemšana

Deal Could Be Announced Imminently, Sources Say -- WSJ

2026. g. 6. janv. 20:40 UTC

Iegādes, apvienošanās, pārņemšana

Eli Lilly in Advanced Talks to Buy Ventyx Biosciences For Over $1B, Sources Say -- WSJ

2026. g. 6. janv. 20:01 UTC

Tirgus saruna

Oil Futures Give Back Post-Venezuela Incursion Gains -- Market Talk

2026. g. 6. janv. 19:52 UTC

Tirgus saruna

U.S. Natural Gas Falls Awaiting Colder Weather -- Market Talk

2026. g. 6. janv. 19:46 UTC

Iegādes, apvienošanās, pārņemšana

Under Armour Stock Rises After the 'Warren Buffet of Canada' Boosts Its Stake -- Barrons.com

2026. g. 6. janv. 19:08 UTC

Iegādes, apvienošanās, pārņemšana

OneStream to Go Private Through $6.4B Hg Acquisition

2026. g. 6. janv. 18:28 UTC

Iegādes, apvienošanās, pārņemšana

These Stocks Are Moving the Most Today: Sandisk, Nvidia, AMD, Palantir, OneStream, SoFi, Microchip, and More -- Barrons.com

2026. g. 6. janv. 17:20 UTC

Tirgus saruna

Peļņas

Financial Services Roundup: Market Talk

2026. g. 6. janv. 17:20 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Health Care Roundup: Market Talk

2026. g. 6. janv. 15:57 UTC

Tirgus saruna

Crude Futures Ease Back From Early Gains -- Market Talk

2026. g. 6. janv. 15:34 UTC

Tirgus saruna

Peļņas

Bank of Montreal Expects to Exit 2027 With ROE Hitting 15% Target -- Market Talk

2026. g. 6. janv. 15:27 UTC

Tirgus saruna

German Inflation Won't Fall Much Further in 2026 -- Market Talk

Salīdzinājums

Cenas izmaiņa

Revvity Inc Prognoze

Cenas mērķis

By TipRanks

6.51% augšup

Prognoze 12 mēnešiem

Vidējais 111.89 USD 6.51%

Augstākais 123 USD

Zemākais 100 USD

Pamatojoties uz 11 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Revvity Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

11 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 11 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Revvity Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

51 / 373 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Revvity Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.